UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Patel B
(2022)
Shared genetic susceptibility between trigger finger and carpal tunnel syndrome: a genome-wide association study.
in The Lancet. Rheumatology
Patel K
(2021)
Increasing adiposity and the presence of cardiometabolic morbidity is associated with increased Covid-19-related mortality: results from the UK Biobank
in BMC Endocrine Disorders
Patel KA
(2022)
PLIN1 Haploinsufficiency Causes a Favorable Metabolic Profile.
in The Journal of clinical endocrinology and metabolism
Patel KHK
(2022)
Increasing Adiposity Is Associated With QTc Interval Prolongation and Increased Ventricular Arrhythmic Risk in the Context of Metabolic Dysfunction: Results From the UK Biobank.
in Frontiers in cardiovascular medicine
Patel R
(2022)
Reproducible disease phenotyping at scale: Example of coronary artery disease in UK Biobank
in PLOS ONE
Pathak GA
(2022)
Genetically regulated multi-omics study for symptom clusters of posttraumatic stress disorder highlights pleiotropy with hematologic and cardio-metabolic traits.
in Molecular psychiatry
Patrick MT
(2022)
Enhanced rare disease mapping for phenome-wide genetic association in the UK Biobank.
in Genome medicine
Patxot M
(2021)
Probabilistic inference of the genetic architecture underlying functional enrichment of complex traits
in Nature Communications
Paudel S
(2022)
Associations of changes in physical activity and discretionary screen time with incident obesity and adiposity changes: longitudinal findings from the UK Biobank.
in International journal of obesity (2005)
Pavey H
(2022)
Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank.
in PloS one
Pazoki R
(2019)
GWAS for urinary sodium and potassium excretion highlights pathways shared with cardiovascular traits.
in Nature communications
Pazoki R
(2021)
Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes.
in Nature communications
Pazokitoroudi A
(2021)
Quantifying the contribution of dominance deviation effects to complex trait variation in biobank-scale data.
in American journal of human genetics
Pearce M
(2020)
Estimating physical activity from self-reported behaviours in large-scale population studies using network harmonisation: findings from UK Biobank and associations with disease outcomes.
in The international journal of behavioral nutrition and physical activity
Pearce M
(2021)
Is occupational physical activity associated with mortality in UK Biobank?
in The international journal of behavioral nutrition and physical activity
Peel AJ
(2021)
Comparison of depression and anxiety symptom networks in reporters and non-reporters of lifetime trauma in two samples of differing severity.
in Journal of affective disorders reports
Peeri NC
(2018)
Toenail selenium, genetic variation in selenoenzymes and risk and outcome in glioma.
in Cancer epidemiology
Pei YF
(2020)
The genetic architecture of appendicular lean mass characterized by association analysis in the UK Biobank study.
in Communications biology
Peila R
(2020)
Risk factors for ductal carcinoma in situ of the breast in the UK Biobank cohort study.
in Cancer epidemiology
Peila R
(2020)
Sex hormones, SHBG and risk of colon and rectal cancer among men and women in the UK Biobank.
in Cancer epidemiology
Peila R
(2020)
Diabetes, Glycated Hemoglobin, and Risk of Cancer in the UK Biobank Study.
in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Peila R
(2022)
Association of Prediagnostic Serum Levels of Vitamin D with Risk of Ductal Carcinoma In Situ of the Breast in the UK Biobank Cohort Study.
in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Peila R
(2020)
Association of Sex Hormones with Risk of Cancers of the Pancreas, Kidney, and Brain in the UK Biobank Cohort Study.
in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Peila R
(2022)
Association of a Healthy Lifestyle Index with Risk of Breast Cancer among Women with Normal Body Mass Index in the UK Biobank.
in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Pencina KM
(2023)
Interplay of Atherogenic Particle Number and Particle Size and the Risk of Coronary Heart Disease.
in Clinical chemistry
Peng H
(2022)
Nonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study.
in Metabolism: clinical and experimental
Peng H
(2021)
Accurate brain age prediction with lightweight deep neural networks.
in Medical image analysis
Peng H
(2022)
Plasma Circulating Vitamin C Levels and Risk of Endometrial Cancer: A Bi-Directional Mendelian Randomization Analysis.
in Frontiers in medicine
Peng J
(2023)
The Relationship Between Sleep Traits and Tinnitus in UK Biobank: A Population-Based Cohort Study.
in Ear and hearing
Peng L
(2022)
Insomnia and sleep duration on COVID-19 susceptibility and hospitalization: A Mendelian randomization study.
in Frontiers in public health
Peretz L
(2022)
Deviation of Physiological from Chronological Age Is Associated with Health.
in Studies in health technology and informatics
Perez-Cornago A
(2020)
Examination of potential novel biochemical factors in relation to prostate cancer incidence and mortality in UK Biobank.
in British journal of cancer
Perez-Cornago A
(2022)
Adiposity and risk of prostate cancer death: a prospective analysis in UK Biobank and meta-analysis of published studies.
in BMC medicine
Perez-Cornago A
(2021)
Description of the updated nutrition calculation of the Oxford WebQ questionnaire and comparison with the previous version among 207,144 participants in UK Biobank.
in European journal of nutrition
Perišic MM
(2022)
Polygenic Risk Score and Risk Factors for Gestational Diabetes.
in Journal of personalized medicine
Perišic MM
(2022)
Polygenic Risk Score and Risk Factors for Preeclampsia and Gestational Hypertension.
in Journal of personalized medicine
Perrotta ML
(2020)
Adults With Mild-to-Moderate Congenital Heart Disease Demonstrate Measurable Neurocognitive Deficits.
in Journal of the American Heart Association
Persyn E
(2020)
Genome-wide association study of MRI markers of cerebral small vessel disease in 42,310 participants.
in Nature communications
Pervaiz U
(2020)
Optimising network modelling methods for fMRI.
in NeuroImage
Pervaiz U
(2022)
Multi-dynamic modelling reveals strongly time-varying resting fMRI correlations.
in Medical image analysis
Pessente GD
(2022)
Effect of Occurrence of Lamin A/C (LMNA) Genetic Variants in a Cohort of 101 Consecutive Apparent "Lone AF" Patients: Results and Insights.
in Frontiers in cardiovascular medicine
Petermann-Rocha F
(2021)
Association of sarcopenia with incident osteoporosis: a prospective study of 168,682 UK biobank participants.
in Journal of cachexia, sarcopenia and muscle
Petermann-Rocha F
(2020)
Factors associated with sarcopenia: A cross-sectional analysis using UK Biobank.
in Maturitas
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |